ELIQUIS®

Drug Information Related Patent

Hold Company

BRISTOL MYERS SQUIBB

Dosage and Administration

TABLET;ORAL

Specification

2.5MG; 5MG

Indication

ELIQUIS® can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Use

Instructions for Use

API

APIXABAN

API Structure

We Supply

Note:

In-house Standard/CP/USP/EP/JP
Facility GMP
Product GMP
USMF/ASMF/CADMF/China DMF/DMF/WC/KDMF/CDE

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
6967208	2026/11/21
9326945	2031/2/24

API Patent

Patent No	Expiration Date
6967208	2026/11/21

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Member of